Pamala A Pawloski1, Ann M Geiger2, Reina Haque3, Aruna Kamineni4, Hassan Fouayzi5, Jessica Ogarek5, Hans V Petersen6, Jaclyn L F Bosco7,8, Soe Soe Thwin8,9, Rebecca A Silliman8, Terry S Field5. 1. HealthPartners Institute for Education and Research, Minneapolis, Minnesota. 2. Wake Forest School of Medicine, Winston-Salem, North Carolina. 3. Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California. 4. Group Health Research Institute, Seattle, Washington. 5. Meyers Primary Care Institute, Worcester, Massachusetts. 6. Lovelace Respiratory Research Institute, Albuquerque, New Mexico. 7. Dana-Farber Cancer Institute, Phyllis F. Cantor Center, Boston, Massachusetts. 8. Section of Geriatrics, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts. 9. Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Healthcare System, Boston, Massachusetts.
Abstract
OBJECTIVES: To examine the effect of breast cancer and its treatment on fracture risk in older breast cancer survivors. DESIGN: A 10-year prospective cohort study beginning 5 years after a diagnosis of breast cancer for survivors and match date for comparison women. SETTING: Six integrated healthcare systems. PARTICIPANTS: Women aged 65 and older (1,286 survivors, 1,286 comparison women, mean age 77.7 in both groups, white, non-Hispanic: survivors, 81.6%; comparison women, 85.2%) who were alive and recurrence free 5 years after a diagnosis of early-stage breast cancer and matched on age, study site, and enrollment year to a comparison cohort without breast cancer. MEASUREMENTS: Cox proportional hazards models were used to estimate the association between fracture risk and survivor-comparison status, adjusting for drugs and risk factors associated with bone health. A subanalysis was used to evaluate the association between tamoxifen exposure and fracture risk. RESULTS: No difference was observed in fracture rates between groups (hazard ratio (HR) = 1.1, 95% confidence interval (CI) = 0.9-1.3). The protective effect of tamoxifen was not statistically significant (HR = 0.9, 95% CI = 0.6-1.2). CONCLUSION: Long-term survivors of early-stage breast cancer diagnosed at age 65 and older are not at greater risk of osteoporotic fractures than age-matched women without breast cancer. There appears to be no long-term protection from fractures with tamoxifen use.
OBJECTIVES: To examine the effect of breast cancer and its treatment on fracture risk in older breast cancer survivors. DESIGN: A 10-year prospective cohort study beginning 5 years after a diagnosis of breast cancer for survivors and match date for comparison women. SETTING: Six integrated healthcare systems. PARTICIPANTS: Women aged 65 and older (1,286 survivors, 1,286 comparison women, mean age 77.7 in both groups, white, non-Hispanic: survivors, 81.6%; comparison women, 85.2%) who were alive and recurrence free 5 years after a diagnosis of early-stage breast cancer and matched on age, study site, and enrollment year to a comparison cohort without breast cancer. MEASUREMENTS: Cox proportional hazards models were used to estimate the association between fracture risk and survivor-comparison status, adjusting for drugs and risk factors associated with bone health. A subanalysis was used to evaluate the association between tamoxifen exposure and fracture risk. RESULTS: No difference was observed in fracture rates between groups (hazard ratio (HR) = 1.1, 95% confidence interval (CI) = 0.9-1.3). The protective effect of tamoxifen was not statistically significant (HR = 0.9, 95% CI = 0.6-1.2). CONCLUSION: Long-term survivors of early-stage breast cancer diagnosed at age 65 and older are not at greater risk of osteoporotic fractures than age-matched women without breast cancer. There appears to be no long-term protection from fractures with tamoxifen use.
Authors: Mary S McCabe; Smita Bhatia; Kevin C Oeffinger; Gregory H Reaman; Courtney Tyne; Dana S Wollins; Melissa M Hudson Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Zhao Chen; Michael Maricic; Tamsen L Bassford; Mary Pettinger; Cheryl Ritenbaugh; Ana Maria Lopez; David H Barad; Margery Gass; Meryl S Leboff Journal: Arch Intern Med Date: 2005-03-14
Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: L Joseph Melton; Lynn C Hartmann; Sara J Achenbach; Elizabeth J Atkinson; Terry M Therneau; Sundeep Khosla Journal: J Bone Miner Res Date: 2012-05 Impact factor: 6.741
Authors: Henning Mouridsen; Aparna Keshaviah; Alan S Coates; Manuela Rabaglio; Monica Castiglione-Gertsch; Zhuoxin Sun; Beat Thürlimann; Louis Mauriac; John F Forbes; Robert Paridaens; Richard D Gelber; Marco Colleoni; Ian Smith; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-11-12 Impact factor: 44.544
Authors: Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto Journal: Lancet Date: 2013-03-09 Impact factor: 79.321
Authors: Timothy L Lash; Soe Soe Thwin; Marianne Ulcickas Yood; Ann M Geiger; Jaclyn Bosco; Virginia P Quinn; Terry S Field; Pamala A Pawloski; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2014-03-01 Impact factor: 4.872
Authors: Edoardo Colzani; Mark Clements; Anna L V Johansson; Annelie Liljegren; Wei He; Judith Brand; Jan Adolfsson; Tommy Fornander; Per Hall; Kamila Czene Journal: Br J Cancer Date: 2016-10-04 Impact factor: 7.640
Authors: Cody Ramin; Betty J May; Richard B S Roden; Mikiaila M Orellana; Brenna C Hogan; Michelle S McCullough; Dana Petry; Deborah K Armstrong; Kala Visvanathan Journal: Breast Cancer Res Date: 2018-11-13 Impact factor: 6.466
Authors: Merav Fraenkel; David B Geffen; Victor Novack; Tali Shafat; Yuval Mizrakli; Samuell Ariad; Michael Koretz; Larry Norton; Ethel Siris Journal: NPJ Breast Cancer Date: 2015-07-22